Clinical Trial Update: Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating axitinib for metastatic or unresectable melanoma (including intraocular melanoma) has been terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraocular Melanoma
• Melanoma

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2018-05-09